Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Imminent Q3 2026 earnings call and a strong preliminary CARVYKTI sales print are the dominant near-term catalysts, with positive sentiment offset by the stock's recent low-volume pop and ongoing unprofitability.
Legend Biotech announced it will host an investor conference call on its third quarter 2026 results. This is the key near-term scheduled catalyst; the call will focus investor attention on CARVYKTI revenue trajectory, margin progression, and pipeline commentary, with potential for sharp price moves around the release and guidance.
Legend Biotech Press ReleasesIn a Form 6-K, Legend Biotech disclosed that CARVYKTI generated approximately $710 million in net trade sales for the quarter ended September 30, 2026, based on Janssen-provided data. The figure signals continued strong sequential growth for the flagship product and is likely to be a focal point of the upcoming earnings call, supporting positive sentiment if confirmed in reported revenue.
SEC Filing (Form 6-K)The FDA cleared the IND application for LB2501, a first-in-class dual-targeting CD19/CD20 in vivo CAR-T therapy, enabling a planned U.S. Phase 1/2 study. The milestone advances Legend's next-generation in vivo platform and can support sentiment via pipeline optionality, though near-term financial impact is limited as it is early-stage.
SEC Filing (Form 6-K)Legend Biotech shares rose 4.9% to about $20.22 in midday trading on unusually light volume (~97% below average), with commentary referencing prior quarterly results that beat estimates (EPS $0.09 vs $0.07; revenue $387.5M, +51.9% YoY) while the company remains unprofitable. The low-volume move suggests fragile conviction and potential volatility into the earnings event.
MarketBeat